Fleischer et al. [11], showed a higher CPV at follow-up in untreated MS and in MS on dimethyl-fumarate (DMF), but not with natalizumab – supporting their conclusion that high-efficacy treatment can prevent CP enlargement, likely due to its role in limiting immune cell trafficking into the CNS. The gene discussed is CP; the disease is myeloid sarcoma.